Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395251 | 1.00 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387904 | 1.00 | TACR2 (0.72) | TACR2 | |
| Hydrochloric Acid SCHEMBL5813499 | 0.99 | TACR2 (0.71) | TACR2 | |
| Hydrochloric Acid SCHEMBL6057713 | 0.99 | TACR2 (0.71) | TACR2 | |
| SCHEMBL9217768 | 0.98 | TACR2 (0.71) | TACR2 | |
| Hydrochloric Acid SCHEMBL7045673 | 0.97 | TACR2 (0.70) | TACR2 | |
| Maleic Acid SCHEMBL6057634 | 0.96 | TACR2 (0.67) | TACR2 | |
| Fumaric Acid SCHEMBL6057636 | 0.96 | TACR2 (0.67) | TACR2 | |
| SCHEMBL8437859 | 0.95 | TACR2 (0.74) | TACR2 | |
| SCHEMBL7047293 | 0.95 | TACR2 (0.74) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307202-B1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | claimed |
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | claimed |
| EP-1450805-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | claimed |
| US-20030139433-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | claimed |
| WO-2003037341-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | claimed |
| EP-1307202-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2003-05-07 | — | — | EP | claimed |
| WO-2001097811-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | claimed |
| EP-0714392-B1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LTD (GB) | 1998-11-04 | — | — | EP | claimed |
| JP-H09501439-A | — | — | 1997-02-10 | — | — | JP | claimed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | claimed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | claimed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | claimed |
| EP-1345899-B1 | N-substituted amides as NK1 receptor antagonists | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1276729-B1 | NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1324992-B1 | CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-6090824-A | Therapeutic neurokinin receptor antagonist compounds | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| US-5990130-A | NOVEL 4-SUBSTITUTED PIPERIDINE DERIVATIVES WHICH ANTAGONIZE NEUROKININ; USEFUL IN TREATMENT OF ASMTHMA AND RELATED CONDITIONS | ZENECA LIMITED (GB) | 1999-11-23 | — | — | US | disclosed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | TACR2 2/4885 |
| US-20030139433-A1 | Method for the treatment of overactive bladder | QDPR, PDE3A, HNMT | TACR2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.